Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Lafeber

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Clinical Lipidology|April 22, 2025
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control studyFazil M Alidjan, Sandra den Hoedt, Mardin Rashid, et al.
Blood Pressure|October 24, 2025
Differences in antihypertensive drug blood levels in patients with hypertension (DECISION): a prospective study comparing pharmacokinetics and pharmacodynamics of perindopril in younger and older patientsDimokrat Hassan, Laura E J Peeters, Wim J R Rietdijk, et al.
Frontiers in Immunology|October 25, 2021
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial ProtocolRoos S G Sablerolles, Abraham Goorhuis, Corine H GeurtsvanKessel, et al.
The New England Journal of Medicine|January 19, 2022
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S PrimingRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Frontiers in Immunology|December 16, 2022
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocolNgoc H Tan, Roos S G Sablerolles, Wim J R Rietdijk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2022
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare WorkersRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Iscience|December 12, 2022
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccinationDaryl Geers, Roos S G Sablerolles, Debbie van Baarle, et al.
Nature Communications|May 18, 2024
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boostersLuca M Zaeck, Ngoc H Tan, Wim J R Rietdijk, et al.
The Lancet. Infectious Diseases|April 23, 2023
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trialNgoc H Tan, Daryl Geers, Roos S G Sablerolles, et al.
The Journal of Infection|January 10, 2026
Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccinationDaryl Geers, Muriel Aguilar-Bretones, Luca M Zaeck, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Clinical Lipidology|April 22, 2025
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control studyFazil M Alidjan, Sandra den Hoedt, Mardin Rashid, et al.
Blood Pressure|October 24, 2025
Differences in antihypertensive drug blood levels in patients with hypertension (DECISION): a prospective study comparing pharmacokinetics and pharmacodynamics of perindopril in younger and older patientsDimokrat Hassan, Laura E J Peeters, Wim J R Rietdijk, et al.
Frontiers in Immunology|October 25, 2021
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial ProtocolRoos S G Sablerolles, Abraham Goorhuis, Corine H GeurtsvanKessel, et al.
The New England Journal of Medicine|January 19, 2022
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S PrimingRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Frontiers in Immunology|December 16, 2022
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocolNgoc H Tan, Roos S G Sablerolles, Wim J R Rietdijk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2022
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare WorkersRoos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis, et al.
Iscience|December 12, 2022
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccinationDaryl Geers, Roos S G Sablerolles, Debbie van Baarle, et al.
Nature Communications|May 18, 2024
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boostersLuca M Zaeck, Ngoc H Tan, Wim J R Rietdijk, et al.
The Lancet. Infectious Diseases|April 23, 2023
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trialNgoc H Tan, Daryl Geers, Roos S G Sablerolles, et al.
The Journal of Infection|January 10, 2026
Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccinationDaryl Geers, Muriel Aguilar-Bretones, Luca M Zaeck, et al.
Pageof 4